Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Health | Hematology | Lymphoma | T-cell Lymphoma